Search

Your search keyword '"Bathen TF"' showing total 193 results

Search Constraints

Start Over You searched for: Author "Bathen TF" Remove constraint Author: "Bathen TF"
193 results on '"Bathen TF"'

Search Results

51. Spatial differentiation of metabolism in prostate cancer tissue by MALDI-TOF MSI.

52. Utility of T 2 -weighted MRI texture analysis in assessment of peripheral zone prostate cancer aggressiveness: a single-arm, multicenter study.

53. Detection of Recurrent Prostate Cancer With 18 F-Fluciclovine PET/MRI.

54. A Quality Control System for Automated Prostate Segmentation on T2-Weighted MRI.

55. Modeling the diffusion-weighted imaging signal for breast lesions in the b = 200 to 3000 s/mm 2 range: quality of fit and classification accuracy for different representations.

56. Feasibility of contrast-enhanced MRI derived textural features to predict overall survival in locally advanced breast cancer.

57. Stromal Collagen Content in Breast Tumors Correlates With In Vivo Diffusion-Weighted Imaging: A Comparison of Multi b-Value DWI With Histologic Specimen From Benign and Malignant Breast Lesions.

58. Relative Enhanced Diffusivity in Prostate Cancer: Protocol Optimization and Diagnostic Potential.

59. Effect of exercise training on cardiac metabolism in rats with heart failure.

61. Semi-automatic segmentation from intrinsically-registered 18F-FDG-PET/MRI for treatment response assessment in a breast cancer cohort: comparison to manual DCE-MRI.

62. Simultaneous Detection of Zinc and Its Pathway Metabolites Using MALDI MS Imaging of Prostate Tissue.

63. Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers.

64. Metabolic consequences of perioperative oral carbohydrates in breast cancer patients - an explorative study.

65. Historical Biobanks in Breast Cancer Metabolomics- Challenges and Opportunities.

66. The effect of sampling procedures and day-to-day variations in metabolomics studies of biofluids.

67. Accuracy of breast cancer lesion classification using intravoxel incoherent motion diffusion-weighted imaging is improved by the inclusion of global or local prior knowledge with bayesian methods.

68. Metabolomics Identifies Placental Dysfunction and Confirms Flt-1 (FMS-Like Tyrosine Kinase Receptor 1) Biomarker Specificity.

70. Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients.

71. Effect of Repeated Freeze-Thaw Cycles on NMR-Measured Lipoproteins and Metabolites in Biofluids.

72. Prostate-Specific Membrane Antigen PET/Magnetic Resonance Imaging for the Planning of Salvage Radiotherapy in Patients with Prostate Cancer with Biochemical Recurrence After Radical Prostatectomy.

73. Hyperoxia affects the lung tissue: A porcine histopathological and metabolite study using five hours of apneic oxygenation.

74. Associations of physical activity and sedentary time with lipoprotein subclasses in Norwegian schoolchildren: The Active Smarter Kids (ASK) study.

75. R2* Relaxation Affects Pharmacokinetic Analysis of Dynamic Contrast-Enhanced MRI in Cancer and Underestimates Treatment Response at 7 T.

76. Breast cancer quantitative proteome and proteogenomic landscape.

77. The Effect of Exercise Training on Myocardial and Skeletal Muscle Metabolism by MR Spectroscopy in Rats with Heart Failure.

78. Biomarker Discovery Using NMR-Based Metabolomics of Tissue.

79. Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer.

80. Skeletal muscle metabolism in rats with low and high intrinsic aerobic capacity: Effect of aging and exercise training.

81. The Effect of Including Bone in Dixon-Based Attenuation Correction for 18 F-Fluciclovine PET/MRI of Prostate Cancer.

82. Simultaneous 18 F-fluciclovine Positron Emission Tomography and Magnetic Resonance Spectroscopic Imaging of Prostate Cancer.

83. Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment.

84. Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma.

85. 18 F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients.

86. Multiparametric characterization of response to anti-angiogenic therapy using USPIO contrast-enhanced MRI in combination with dynamic contrast-enhanced MRI.

87. Relative enhanced diffusivity: noise sensitivity, protocol optimization, and the relation to intravoxel incoherent motion.

88. Support vector machine for breast cancer classification using diffusion-weighted MRI histogram features: Preliminary study.

89. Combined 18 F-Fluciclovine PET/MRI Shows Potential for Detection and Characterization of High-Risk Prostate Cancer.

90. Geometric distortion correction in prostate diffusion-weighted MRI and its effect on quantitative apparent diffusion coefficient analysis.

91. Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized.

92. NMR-based metabolomics of biofluids in cancer.

93. In vivo MR spectroscopy predicts high tumor grade in endometrial cancer.

95. APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer.

96. NMR-Based Prostate Cancer Metabolomics.

97. Prediction of Clinical Endpoints in Breast Cancer Using NMR Metabolic Profiles.

98. Non-Invasive Prostate Cancer Characterization with Diffusion-Weighted MRI: Insight from In silico Studies of a Transgenic Mouse Model.

99. Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.

100. SFRP4 gene expression is increased in aggressive prostate cancer.

Catalog

Books, media, physical & digital resources